Contributions
Abstract: PB1887
Type: Publication Only
Background
Aims
To evaluate the efficacy and safety of the bendamustine-rituximab association in a group of patients with follicular lymphoma previously exposed to rituximab.
Methods
Results
41 patients were valid for analysis. Characteristics: 70% males with a mean age of 62 years (30-87). ECOG≤ 2 in 95% of cases, 73.2% in stages III-IV and FLIPI ≥ 3 in 48%. Bulky mass in 13% of patients, LDH and β2-microglobulin increased by 12% and 41.2% respectively and bone marrow involvement in 60%. 68% had received only one previous treatment, with an average of 1.7 (1-5) and the most frequent was CHOP-R in 66% followed by CVP-R in 11%. All patients had previously received rituximab and only 3 patients (7.3%) could be considered refractory. All patients received BR (B-90 mg / m2 D1-2, R-375mg / m2 D1). Median cycles 5.1 (1-6). Support with G-CSF was used in 27.5% of cycles. Maintenance with rituximab after obtaining a complete (CR) or partial remission (PR) was administered in 42% of patients. Response: The overall response rate was 95.1% (65.8% CR-iCR / 29.3% PR). With a median follow-up of 25 months (6-92) the median response duration was 41.9 months (32.8-51.1) and the median progression-free survival (PFS) was 57 months (27.4-86.5) with no impact neither by the number of previous treatments (1 vs ≥2) (P = 0.69) nor by the age (<70 vs ≥ 70) (P = 0.9). Patients who received maintenance with rituximab after BR had a significantly longer median PFS than without (NR vs 32) (p = 0.004). Toxicity: No treatment-related death was recorded. 42% and 36.6% of the patients presented G3-4 neutropenia and thrombocytopenia respectively, although only 2 patients were admitted due to febrile neutropenia. 43% received cotrimoxazole prophylaxis and 3 opportunistic infections were recorded (1 P. jirovecii pneumonia in a patient without prophylaxis).
Conclusion
BR has a high efficacy and a good safety profile in this series of patients with relapsed FL previously exposed to rituximab. The number of previous treatments (1 vs ≥ 2) and the age had no impact in the results.
Session topic: 19. Indolent Non-Hodgkin lymphoma - Clinical
Keyword(s): Follicular lymphoma
Abstract: PB1887
Type: Publication Only
Background
Aims
To evaluate the efficacy and safety of the bendamustine-rituximab association in a group of patients with follicular lymphoma previously exposed to rituximab.
Methods
Results
41 patients were valid for analysis. Characteristics: 70% males with a mean age of 62 years (30-87). ECOG≤ 2 in 95% of cases, 73.2% in stages III-IV and FLIPI ≥ 3 in 48%. Bulky mass in 13% of patients, LDH and β2-microglobulin increased by 12% and 41.2% respectively and bone marrow involvement in 60%. 68% had received only one previous treatment, with an average of 1.7 (1-5) and the most frequent was CHOP-R in 66% followed by CVP-R in 11%. All patients had previously received rituximab and only 3 patients (7.3%) could be considered refractory. All patients received BR (B-90 mg / m2 D1-2, R-375mg / m2 D1). Median cycles 5.1 (1-6). Support with G-CSF was used in 27.5% of cycles. Maintenance with rituximab after obtaining a complete (CR) or partial remission (PR) was administered in 42% of patients. Response: The overall response rate was 95.1% (65.8% CR-iCR / 29.3% PR). With a median follow-up of 25 months (6-92) the median response duration was 41.9 months (32.8-51.1) and the median progression-free survival (PFS) was 57 months (27.4-86.5) with no impact neither by the number of previous treatments (1 vs ≥2) (P = 0.69) nor by the age (<70 vs ≥ 70) (P = 0.9). Patients who received maintenance with rituximab after BR had a significantly longer median PFS than without (NR vs 32) (p = 0.004). Toxicity: No treatment-related death was recorded. 42% and 36.6% of the patients presented G3-4 neutropenia and thrombocytopenia respectively, although only 2 patients were admitted due to febrile neutropenia. 43% received cotrimoxazole prophylaxis and 3 opportunistic infections were recorded (1 P. jirovecii pneumonia in a patient without prophylaxis).
Conclusion
BR has a high efficacy and a good safety profile in this series of patients with relapsed FL previously exposed to rituximab. The number of previous treatments (1 vs ≥ 2) and the age had no impact in the results.
Session topic: 19. Indolent Non-Hodgkin lymphoma - Clinical
Keyword(s): Follicular lymphoma